This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September 2026 quarter revenue rose 30% from a year earlier; net loss widened
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On the consolidated basis for the quarter ended September 30, 2026, revenue from operations was Rs 119.86 lakh, up 30.4% from Rs 91.92 lakh a year earlier, and the net loss widened 38.3% to Rs 10,694.21 lakh. The loss before interest, depreciation and tax widened from 86.8% to 92.5% of revenue. In the consolidated half year ended September 30, 2026, net cash used in operations was Rs 22,181.28 lakh.
The revenue rise helps, but the wider loss and large operating cash outflow may pressure investor sentiment and the share price.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹1.20 Cr | ₹0.92 Cr | +30.4% |
| Profit after tax | −₹106.9 Cr | −₹77.31 Cr | loss widened |
From the company's XBRL filing, not from the text above. Operating profit and EBITDA margin are not shown for banks and lenders, whose other income is their business.